Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • Lyell Immunopharma's Other Non-Current Liabilities fell 2479.66% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 2479.66%. This contributed to the annual value of $3.3 million for FY2024, which is 1121.72% down from last year.
  • Lyell Immunopharma's Other Non-Current Liabilities amounted to $2.7 million in Q3 2025, which was down 2479.66% from $3.0 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Non-Current Liabilities registered a high of $5.0 million during Q3 2021, and its lowest value of $900000.0 during Q2 2021.
  • In the last 5 years, Lyell Immunopharma's Other Non-Current Liabilities had a median value of $3.7 million in 2023 and averaged $3.6 million.
  • Per our database at Business Quant, Lyell Immunopharma's Other Non-Current Liabilities surged by 75827.07% in 2021 and then plummeted by 2479.66% in 2025.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Other Non-Current Liabilities stood at $4.6 million in 2021, then dropped by 9.92% to $4.1 million in 2022, then fell by 10.92% to $3.7 million in 2023, then fell by 11.22% to $3.3 million in 2024, then decreased by 17.58% to $2.7 million in 2025.
  • Its Other Non-Current Liabilities stands at $2.7 million for Q3 2025, versus $3.0 million for Q2 2025 and $3.1 million for Q1 2025.